Daniel Modin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Modin has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
- Tor Biering-Sørensen
Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, 2900 Hellerup, Denmark
38 shared publications - Niklas Dyrby Johansen
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark
19 shared publications - Jens-Ulrik Stæhr Jensen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen
17 shared publications - Lars Køber
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
15 shared publications - Scott D. Solomon
Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (S.D.S.).
13 shared publications - Gunnar Hilmar Gislason
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte , Hospitalsvej 1, 2900 Hellerup
12 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (11)
Electronic Nudges to Increase Influenza Vaccination Uptake in Young and Middle-Aged Patients With Heart Failure: A Prespecified Analysis of the NUDGE-FLU-CHRONIC Trial
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (11)
Open AccessElectronic Nudges to Increase Influenza Vaccination Uptake in Young and Middle-Aged Patients With Heart Failure: A Prespecified Analysis of the NUDGE-FLU-CHRONIC Trial
- Open Access
- 6 October 2026
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 7 (9)
RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial
- 6 October 2026
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 7 (9)
Open AccessRSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial
- 29 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Sex differences in statin treatment after myocardial infarction in Denmark: a time-trend study utilizing Danish national registries
Introduction: Sex differences in treatment with statins after myocardial infarction (MI) are widely recognized. This study aimed to assess differences in statin treatment initiation after MI by sex, age groups, and year of MI. Methods and results: We conducted a cohort study in Denmark using registries for patients with a first-time MI between 1 January 2000 and 31 December 2024, excluding patients already treated with lipid-lowering drugs up to 180 days before their MI. Descriptive statistics and multivariable Poisson regression were used to explore the effect of sex on treatment initiation. A total of 154 591 patients were included in the study (37% females, median age 75 years for females and 65 years for men). Overall, 54% of females vs. 72% of males had initiated statin treatment within 180 days (P < 0.001). For females ≥40 years, significantly lower proportions were found in every year interval (P < 0.001 for all). Within the age groups, the relative difference between the sexes increased from 2000–2 until 2015–9, whereafter a decrease was found from 2015–9 to 2020–4, except among 60–69-year-olds for whom the decrease began earlier, starting in 2010–4. Females had a 25% lower relative risk (RR 0.75 [0.74; 0.76]) of initiating treatment. These differences remained after adjusting for age groups and year interval (RR 0.87 [0.86; 0.87]) and after further adjustment for baseline characteristics (RR 0.91 [0.85; 99]). Conclusion: A smaller proportion of females received statins than males after an MI. Disparities in treatment persisted over the years.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Sex differences in statin treatment after myocardial infarction in Denmark: a time-trend study utilizing Danish national registries
Introduction: Sex differences in treatment with statins after myocardial infarction (MI) are widely recognized. This study aimed to assess differences in statin treatment initiation after MI by sex, age groups, and year of MI. Methods and results: We conducted a cohort study in Denmark using registries for patients with a first-time MI between 1 January 2000 and 31 December 2024, excluding patients already treated with lipid-lowering drugs up to 180 days before their MI. Descriptive statistics and multivariable Poisson regression were used to explore the effect of sex on treatment initiation. A total of 154 591 patients were included in the study (37% females, median age 75 years for females and 65 years for men). Overall, 54% of females vs. 72% of males had initiated statin treatment within 180 days (P < 0.001). For females ≥40 years, significantly lower proportions were found in every year interval (P < 0.001 for all). Within the age groups, the relative difference between the sexes increased from 2000–2 until 2015–9, whereafter a decrease was found from 2015–9 to 2020–4, except among 60–69-year-olds for whom the decrease began earlier, starting in 2010–4. Females had a 25% lower relative risk (RR 0.75 [0.74; 0.76]) of initiating treatment. These differences remained after adjusting for age groups and year interval (RR 0.87 [0.86; 0.87]) and after further adjustment for baseline characteristics (RR 0.91 [0.85; 99]). Conclusion: A smaller proportion of females received statins than males after an MI. Disparities in treatment persisted over the years.
- Open Access
- 18 June 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial
Aims: Atrial fibrillation (AF) is a risk factor for respiratory syncytial virus (RSV)-related adverse cardiac events. This prespecified analysis of the DAN-RSV trial investigated RSVpreF vaccine effectiveness (VE) against respiratory and cardiovascular outcomes among older adults with and without AF. Methods and Results: DAN-RSV was a pragmatic, open-label, individually randomized trial in Denmark during the 2024/2025 winter season. Adults ≥60 years were randomly assigned 1:1 to RSVpreF vaccine or no vaccine. Baseline and endpoint data were obtained from nationwide health registries. The primary endpoint was hospitalization for RSV-related respiratory tract disease, occurring 14 days after study visit until May 31, 2025. Prespecified respiratory and cardiovascular endpoints were assessed by AF status. Among 131,276 participants, 10,126 (7.7%) had a history of AF (mean age 73.2 ± 6.9 years, 30.4% female). AF participants had higher event rates compared with non-AF participants. RSVpreF vaccine lowered the incidence of the primary endpoint with no evidence of effect modification by AF status (AF: VE 80.6% (95%CI -84.7 to 99.6), no AF: VE 84.6% (95%CI 32.3 to 98.3), p-value for interaction >0.99). RSVpreF vaccine was further associated with a lower incidence of all-cause respiratory tract disease hospitalization (AF: VE 25.7% (95%CI -16.9 to 46.1), no AF: VE 13.0% (95%CI -3.3 to 27.8)) and RSV-related and overall cardio-respiratory disease hospitalization with no evidence of effect modification by AF status (p-value for interaction ≥0.45 for all). RSVpreF vaccine was not significantly associated with AF or stroke hospitalizations regardless of AF status (p-value for interaction≥0.34 for all). Conclusions: In older adults, RSVpreF vaccine was associated with a lower incidence of RSV-related and all-cause respiratory tract disease hospitalizations, as well as RSV-related and all-cause cardio-respiratory disease hospitalizations, with no evidence of effect modification by AF status.
- 18 June 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessEffect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial
Aims: Atrial fibrillation (AF) is a risk factor for respiratory syncytial virus (RSV)-related adverse cardiac events. This prespecified analysis of the DAN-RSV trial investigated RSVpreF vaccine effectiveness (VE) against respiratory and cardiovascular outcomes among older adults with and without AF. Methods and Results: DAN-RSV was a pragmatic, open-label, individually randomized trial in Denmark during the 2024/2025 winter season. Adults ≥60 years were randomly assigned 1:1 to RSVpreF vaccine or no vaccine. Baseline and endpoint data were obtained from nationwide health registries. The primary endpoint was hospitalization for RSV-related respiratory tract disease, occurring 14 days after study visit until May 31, 2025. Prespecified respiratory and cardiovascular endpoints were assessed by AF status. Among 131,276 participants, 10,126 (7.7%) had a history of AF (mean age 73.2 ± 6.9 years, 30.4% female). AF participants had higher event rates compared with non-AF participants. RSVpreF vaccine lowered the incidence of the primary endpoint with no evidence of effect modification by AF status (AF: VE 80.6% (95%CI -84.7 to 99.6), no AF: VE 84.6% (95%CI 32.3 to 98.3), p-value for interaction >0.99). RSVpreF vaccine was further associated with a lower incidence of all-cause respiratory tract disease hospitalization (AF: VE 25.7% (95%CI -16.9 to 46.1), no AF: VE 13.0% (95%CI -3.3 to 27.8)) and RSV-related and overall cardio-respiratory disease hospitalization with no evidence of effect modification by AF status (p-value for interaction ≥0.45 for all). RSVpreF vaccine was not significantly associated with AF or stroke hospitalizations regardless of AF status (p-value for interaction≥0.34 for all). Conclusions: In older adults, RSVpreF vaccine was associated with a lower incidence of RSV-related and all-cause respiratory tract disease hospitalizations, as well as RSV-related and all-cause cardio-respiratory disease hospitalizations, with no evidence of effect modification by AF status.
- Open Access
- 30 April 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial
Aims: Respiratory syncytial virus (RSV) is a common cause of severe illness in older adults and may cause extra-pulmonary complications. Individuals with chronic kidney disease (CKD) are at increased risk of severe outcomes from respiratory infections, but RSV-specific data are limited. This prespecified analysis of the DAN-RSV trial evaluated the RSV prefusion F protein–based vaccine (RSVpreF) effectiveness (VE) in adults aged ≥60 years with and without CKD. Methods and results: The DAN-RSV trial was a pragmatic, open-label, parallel-group, individually randomized clinical trial conducted during 2024/25. Adults aged ≥60 years were randomized 1:1 to receive respiratory syncytial virus prefusion F (RSVpreF) or no vaccine. Chronic kidney disease was identified using diagnosis codes and biomarkers. Outcomes were assessed through nationwide registry linkage from 14 days post-randomization to 31 May 2025. The primary outcome was RSV-related respiratory tract disease hospitalization; secondary outcomes included respiratory, cardiovascular, and kidney-related hospitalizations, and all-cause mortality. Among 131 276 participants (65 642 RSVpreF; 65 634 controls), 13 364 (10.2%) had CKD. Chronic kidney disease participants were older and had more comorbidities. Hospitalization rates were consistently higher among those with CKD. RSVpreF compared with no vaccine reduced RSV-related respiratory tract disease hospitalization [overall VE: 83.3% (95% confidence interval, CI: 42.9–96.9%); CKD VE: 66.4% (95% CI: −85.2 to 96.7%); no CKD VE: 91.7% (95% CI: 43.7 to99.8%), Pinteraction = 0.29], and cardiorespiratory hospitalization, irrespective of CKD status. Among participants with CKD, a numerical imbalance in mortality was observed; however, event numbers were limited. Conclusion: In this analysis of the DAN-RSV trial, RSVpreF vaccination reduced RSV-related, broader respiratory and cardiorespiratory hospitalizations in older including those with CKD. No significant differences were observed for acute kidney outcomes.
- 30 April 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessRespiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial
Aims: Respiratory syncytial virus (RSV) is a common cause of severe illness in older adults and may cause extra-pulmonary complications. Individuals with chronic kidney disease (CKD) are at increased risk of severe outcomes from respiratory infections, but RSV-specific data are limited. This prespecified analysis of the DAN-RSV trial evaluated the RSV prefusion F protein–based vaccine (RSVpreF) effectiveness (VE) in adults aged ≥60 years with and without CKD. Methods and results: The DAN-RSV trial was a pragmatic, open-label, parallel-group, individually randomized clinical trial conducted during 2024/25. Adults aged ≥60 years were randomized 1:1 to receive respiratory syncytial virus prefusion F (RSVpreF) or no vaccine. Chronic kidney disease was identified using diagnosis codes and biomarkers. Outcomes were assessed through nationwide registry linkage from 14 days post-randomization to 31 May 2025. The primary outcome was RSV-related respiratory tract disease hospitalization; secondary outcomes included respiratory, cardiovascular, and kidney-related hospitalizations, and all-cause mortality. Among 131 276 participants (65 642 RSVpreF; 65 634 controls), 13 364 (10.2%) had CKD. Chronic kidney disease participants were older and had more comorbidities. Hospitalization rates were consistently higher among those with CKD. RSVpreF compared with no vaccine reduced RSV-related respiratory tract disease hospitalization [overall VE: 83.3% (95% confidence interval, CI: 42.9–96.9%); CKD VE: 66.4% (95% CI: −85.2 to 96.7%); no CKD VE: 91.7% (95% CI: 43.7 to99.8%), Pinteraction = 0.29], and cardiorespiratory hospitalization, irrespective of CKD status. Among participants with CKD, a numerical imbalance in mortality was observed; however, event numbers were limited. Conclusion: In this analysis of the DAN-RSV trial, RSVpreF vaccination reduced RSV-related, broader respiratory and cardiorespiratory hospitalizations in older including those with CKD. No significant differences were observed for acute kidney outcomes.
- 12 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , 321-330
Electronic Nudges to Increase Influenza Vaccination in Immunosuppressed Adults Across the Age Spectrum: A Pooled Analysis of Two Nationwide Randomized Trials
Background: Immunosuppressed individuals face higher risk of severe influenza complications, yet vaccination coverage remains low. We aimed to assess the effect of electronic letter-based nudges on influenza vaccination uptake by immunosuppression status. Methods: We performed a participant-level pooled analysis of two methodologically harmonized, nationwide, pragmatic randomized clinical trials (NUDGE-FLU-2 and NUDGE-FLU-CHRONIC) conducted during the 2023–2024 influenza season. Adults aged ≥65 years (NUDGE-FLU-2) and adults aged 18–64 years with chronic conditions (NUDGE-FLU-CHRONIC) were included, with immunosuppression defined by an immunosuppressive diagnosis or a filled prescription for immunosuppressive therapy. Participants were randomized in a 2.45:1:1:1:1:1:1 ratio to usual care or one of six electronic letter interventions. The primary outcome was receipt of influenza vaccination by January 1, 2024, ascertained from nationwide administrative health registries. Effect modification by immunosuppression status was assessed using binomial regression. Results: Among 1,181,254 participants (mean age 67 years; 73,830 [6.3%] immunosuppressed), 66.1% were vaccinated. Any letter increased vaccine uptake compared with usual care (absolute difference, 2.79 percentage points; 95% CI, 2.60–2.98; p<0.001), with greater effect among immunosuppressed individuals (+4.12 vs +2.70 percentage points; pinteraction=0.002). In younger adults with chronic conditions, letter-based nudges increased vaccination rates by 11.7 percentage points overall and by 13.3 percentage points among those with immunosuppression (pinteraction=0.007). Among immunosuppressed individuals, nudging effects appeared greater for those with immunosuppressive conditions than for those receiving immunosuppressive treatment. Conclusions: Electronic letter-based nudges increased influenza vaccination rates, with greater benefit among individuals with immunosuppression. These findings support implementation of low-cost, letter-based nudging strategies to improve vaccine uptake in this high-risk population.
- 12 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , 321-330
Electronic Nudges to Increase Influenza Vaccination in Immunosuppressed Adults Across the Age Spectrum: A Pooled Analysis of Two Nationwide Randomized Trials
Background: Immunosuppressed individuals face higher risk of severe influenza complications, yet vaccination coverage remains low. We aimed to assess the effect of electronic letter-based nudges on influenza vaccination uptake by immunosuppression status. Methods: We performed a participant-level pooled analysis of two methodologically harmonized, nationwide, pragmatic randomized clinical trials (NUDGE-FLU-2 and NUDGE-FLU-CHRONIC) conducted during the 2023–2024 influenza season. Adults aged ≥65 years (NUDGE-FLU-2) and adults aged 18–64 years with chronic conditions (NUDGE-FLU-CHRONIC) were included, with immunosuppression defined by an immunosuppressive diagnosis or a filled prescription for immunosuppressive therapy. Participants were randomized in a 2.45:1:1:1:1:1:1 ratio to usual care or one of six electronic letter interventions. The primary outcome was receipt of influenza vaccination by January 1, 2024, ascertained from nationwide administrative health registries. Effect modification by immunosuppression status was assessed using binomial regression. Results: Among 1,181,254 participants (mean age 67 years; 73,830 [6.3%] immunosuppressed), 66.1% were vaccinated. Any letter increased vaccine uptake compared with usual care (absolute difference, 2.79 percentage points; 95% CI, 2.60–2.98; p<0.001), with greater effect among immunosuppressed individuals (+4.12 vs +2.70 percentage points; pinteraction=0.002). In younger adults with chronic conditions, letter-based nudges increased vaccination rates by 11.7 percentage points overall and by 13.3 percentage points among those with immunosuppression (pinteraction=0.007). Among immunosuppressed individuals, nudging effects appeared greater for those with immunosuppressive conditions than for those receiving immunosuppressive treatment. Conclusions: Electronic letter-based nudges increased influenza vaccination rates, with greater benefit among individuals with immunosuppression. These findings support implementation of low-cost, letter-based nudging strategies to improve vaccine uptake in this high-risk population.
- Top Cited PapersOpen Access
- 17 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (11) , 798-806
High-Dose Versus Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis
BACKGROUND: The high-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior protection against a range of hospitalization end points versus standard-dose inactivated influenza vaccine (SD-IIV), but its effectiveness against specific cardiovascular outcomes and in those with pre-existing cardiovascular disease (CVD) is not well elucidated. METHODS: In a prespecified secondary analysis of the FLUNITY-HD (Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes) individual-level pooled data set integrating 2 methodologically harmonized pragmatic, individually randomized trials conducted in Denmark and Spain, we investigated the relative vaccine effectiveness of HD-IIV versus SD-IIV against severe cardiovascular outcomes and according to pre-existing CVD among adults ≥65 years of age. Data were primarily obtained from routine health care databases, with follow-up from 14 days after vaccination to May 31 the following year. RESULTS: The pooled data set encompassed 466 320 individually randomized participants, of whom 107 700 (23.1%) had a history of CVD. HD-IIV reduced the incidence of hospitalization for influenza or pneumonia, cardiorespiratory disease, laboratory-confirmed influenza, and any cause compared with SD-IIV, irrespective of the presence or absence of pre-existing CVD ( P interaction >0.66 for all outcomes). Compared with the SD-IIV group, the HD-IIV group had a significantly lower incidence of hospitalization for any CVD (HD-IIV, 1.15%, versus SD-IIV, 1.24%; relative vaccine effectiveness, 6.6% [95% CI, 1.6–11.4]; P =0.010), hospitalization for any respiratory disease (HD-IIV, 0.92%, versus SD-IIV, 0.98%; relative vaccine effectiveness, 6.5% [95% CI, 0.7–11.9]; P =0.027), and hospitalization for heart failure (HD-IIV, 0.11%, versus SD-IIV, 0.15%; relative vaccine effectiveness, 21.3% [95% CI, 7.6–33.0]; P =0.003). CONCLUSIONS: In a prespecified pooled analysis of 466 320 individually randomized older adults, HD-IIV reduced the incidence of a wide range of severe cardiovascular and respiratory outcomes compared with SD-IIV, with consistent findings regardless of previous history of CVD. Among cardiovascular outcomes, the protective effect of HD-IIV versus SD-IIV was particularly pronounced against hospitalization for heart failure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06506812.
- 17 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (11) , 798-806
Top Cited PapersOpen AccessHigh-Dose Versus Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis
BACKGROUND: The high-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior protection against a range of hospitalization end points versus standard-dose inactivated influenza vaccine (SD-IIV), but its effectiveness against specific cardiovascular outcomes and in those with pre-existing cardiovascular disease (CVD) is not well elucidated. METHODS: In a prespecified secondary analysis of the FLUNITY-HD (Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes) individual-level pooled data set integrating 2 methodologically harmonized pragmatic, individually randomized trials conducted in Denmark and Spain, we investigated the relative vaccine effectiveness of HD-IIV versus SD-IIV against severe cardiovascular outcomes and according to pre-existing CVD among adults ≥65 years of age. Data were primarily obtained from routine health care databases, with follow-up from 14 days after vaccination to May 31 the following year. RESULTS: The pooled data set encompassed 466 320 individually randomized participants, of whom 107 700 (23.1%) had a history of CVD. HD-IIV reduced the incidence of hospitalization for influenza or pneumonia, cardiorespiratory disease, laboratory-confirmed influenza, and any cause compared with SD-IIV, irrespective of the presence or absence of pre-existing CVD ( P interaction >0.66 for all outcomes). Compared with the SD-IIV group, the HD-IIV group had a significantly lower incidence of hospitalization for any CVD (HD-IIV, 1.15%, versus SD-IIV, 1.24%; relative vaccine effectiveness, 6.6% [95% CI, 1.6–11.4]; P =0.010), hospitalization for any respiratory disease (HD-IIV, 0.92%, versus SD-IIV, 0.98%; relative vaccine effectiveness, 6.5% [95% CI, 0.7–11.9]; P =0.027), and hospitalization for heart failure (HD-IIV, 0.11%, versus SD-IIV, 0.15%; relative vaccine effectiveness, 21.3% [95% CI, 7.6–33.0]; P =0.003). CONCLUSIONS: In a prespecified pooled analysis of 466 320 individually randomized older adults, HD-IIV reduced the incidence of a wide range of severe cardiovascular and respiratory outcomes compared with SD-IIV, with consistent findings regardless of previous history of CVD. Among cardiovascular outcomes, the protective effect of HD-IIV versus SD-IIV was particularly pronounced against hospitalization for heart failure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06506812.
- Top Cited Papers
- 8 January 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 394 (2) , 138-151
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
Respiratory syncytial virus (RSV) can cause serious illness in older adults. The bivalent RSV prefusion F protein-based vaccine (RSVpreF) has been shown to prevent RSV-associated respiratory illness, but data from randomized trials with regard to its effect on outcomes involving hospitalization are limited. In this pragmatic, open-label trial with individual randomization, participants who were 60 years of age or older were assigned in a 1:1 ratio to receive the RSVpreF vaccine (the RSVpreF group) or no vaccine (the control group) during the 2024-2025 winter season. Baseline and outcome data were collected with the use of national registries. The primary end point was hospitalization for RSV-related respiratory tract disease. Secondary end points included hospitalization for RSV-related lower respiratory tract disease and hospitalization for respiratory tract disease from any cause. The prespecified criterion for success for the primary end point and RSV-related secondary end points was a minimum vaccine effectiveness of greater than 20%. Of 131,379 participants who underwent randomization, 131,276 were included in the intention-to-treat population. During follow-up, hospitalization for RSV-related respiratory tract disease occurred in 3 of 65,642 participants in the RSVpreF group and in 18 of 65,634 participants in the control group (0.11 events vs. 0.66 events per 1000 participant-years; vaccine effectiveness, 83.3%; 95% confidence interval [CI], 42.9 to 96.9; P = 0.007 for minimum effectiveness of >20%). The RSVpreF group also had fewer hospitalizations for RSV-related lower respiratory tract disease than the control group (1 vs. 12; vaccine effectiveness, 91.7%; 95% CI, 43.7 to 99.8; P = 0.009 for minimum effectiveness of >20%), as well as fewer hospitalizations for respiratory tract disease from any cause (284 vs. 335; vaccine effectiveness, 15.2%; 95% CI, 0.5 to 27.9; P = 0.04 for vaccine effectiveness of >0%). The incidence of serious adverse events was similar in the two groups. Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine. (Funded by Pfizer; European Union Clinical Trials number, 2024-516600-42-00; DAN-RSV ClinicalTrials.gov number, NCT06684743.).
- 8 January 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 394 (2) , 138-151
Top Cited PapersRSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
Respiratory syncytial virus (RSV) can cause serious illness in older adults. The bivalent RSV prefusion F protein-based vaccine (RSVpreF) has been shown to prevent RSV-associated respiratory illness, but data from randomized trials with regard to its effect on outcomes involving hospitalization are limited. In this pragmatic, open-label trial with individual randomization, participants who were 60 years of age or older were assigned in a 1:1 ratio to receive the RSVpreF vaccine (the RSVpreF group) or no vaccine (the control group) during the 2024-2025 winter season. Baseline and outcome data were collected with the use of national registries. The primary end point was hospitalization for RSV-related respiratory tract disease. Secondary end points included hospitalization for RSV-related lower respiratory tract disease and hospitalization for respiratory tract disease from any cause. The prespecified criterion for success for the primary end point and RSV-related secondary end points was a minimum vaccine effectiveness of greater than 20%. Of 131,379 participants who underwent randomization, 131,276 were included in the intention-to-treat population. During follow-up, hospitalization for RSV-related respiratory tract disease occurred in 3 of 65,642 participants in the RSVpreF group and in 18 of 65,634 participants in the control group (0.11 events vs. 0.66 events per 1000 participant-years; vaccine effectiveness, 83.3%; 95% confidence interval [CI], 42.9 to 96.9; P = 0.007 for minimum effectiveness of >20%). The RSVpreF group also had fewer hospitalizations for RSV-related lower respiratory tract disease than the control group (1 vs. 12; vaccine effectiveness, 91.7%; 95% CI, 43.7 to 99.8; P = 0.009 for minimum effectiveness of >20%), as well as fewer hospitalizations for respiratory tract disease from any cause (284 vs. 335; vaccine effectiveness, 15.2%; 95% CI, 0.5 to 27.9; P = 0.04 for vaccine effectiveness of >0%). The incidence of serious adverse events was similar in the two groups. Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine. (Funded by Pfizer; European Union Clinical Trials number, 2024-516600-42-00; DAN-RSV ClinicalTrials.gov number, NCT06684743.).
- Top Cited Papers
- 11 December 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (23) , 2303-2312
High-Dose Influenza Vaccine to Reduce Hospitalizations
Superior protection against laboratory-confirmed influenza has been proved for high-dose inactivated influenza vaccine, as compared with the standard dose, among adults 65 years of age or older. However, data on the relative effectiveness of the high-dose vaccine against severe clinical outcomes, including hospitalizations, are limited. We conducted a pragmatic, registry-based, open-label, randomized, active-controlled trial to evaluate the relative effectiveness of high-dose inactivated influenza vaccine, as compared with the standard dose, against severe clinical outcomes among community-dwelling adults 65 to 79 years of age. The trial was performed during two influenza seasons (2023-2024 and 2024-2025) with regional health registry data in Galicia, Spain. In each influenza season, the participants were randomly assigned in a 1:1 ratio to receive high-dose inactivated influenza vaccine or the standard dose. The primary end point was a composite of hospitalization for influenza or pneumonia from 14 days after vaccination to May 31 of the following year. A total of 103,169 unique participants underwent randomization; 31,307 participants were enrolled in both seasons and were counted for each. During the 2023-2024 and 2024-2025 seasons, 59,490 and 74,986 participants, respectively, underwent randomization. Among the participants, the mean (±SD) age was 72.3±4.3 years, and 53.6% were men. A primary end-point event occurred in 174 of 67,093 participants (absolute risk, 0.26%) in the high-dose group and in 227 of 66,789 (absolute risk, 0.34%) in the standard-dose group (relative vaccine effectiveness, 23.7%; 95% confidence interval [CI], 6.6 to 37.7). Hospitalization for influenza occurred in 63 of 67,093 participants (absolute risk, 0.09%) in the high-dose group and in 92 of 66,789 (absolute risk, 0.14%) in the standard-dose group (relative vaccine effectiveness, 31.8%; 95% CI, 5.0 to 51.3). The incidence of serious adverse events appeared to be similar in the two trial groups. Among community-dwelling adults 65 to 79 years of age, there appeared to be fewer hospitalizations for influenza or pneumonia with high-dose inactivated influenza vaccine than with the standard dose. (Funded by Sanofi; GALFLU ClinicalTrials.gov number NCT06141655; EudraCT number, 2023-506977-36-00.).
- 11 December 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (23) , 2303-2312
Top Cited PapersHigh-Dose Influenza Vaccine to Reduce Hospitalizations
Superior protection against laboratory-confirmed influenza has been proved for high-dose inactivated influenza vaccine, as compared with the standard dose, among adults 65 years of age or older. However, data on the relative effectiveness of the high-dose vaccine against severe clinical outcomes, including hospitalizations, are limited. We conducted a pragmatic, registry-based, open-label, randomized, active-controlled trial to evaluate the relative effectiveness of high-dose inactivated influenza vaccine, as compared with the standard dose, against severe clinical outcomes among community-dwelling adults 65 to 79 years of age. The trial was performed during two influenza seasons (2023-2024 and 2024-2025) with regional health registry data in Galicia, Spain. In each influenza season, the participants were randomly assigned in a 1:1 ratio to receive high-dose inactivated influenza vaccine or the standard dose. The primary end point was a composite of hospitalization for influenza or pneumonia from 14 days after vaccination to May 31 of the following year. A total of 103,169 unique participants underwent randomization; 31,307 participants were enrolled in both seasons and were counted for each. During the 2023-2024 and 2024-2025 seasons, 59,490 and 74,986 participants, respectively, underwent randomization. Among the participants, the mean (±SD) age was 72.3±4.3 years, and 53.6% were men. A primary end-point event occurred in 174 of 67,093 participants (absolute risk, 0.26%) in the high-dose group and in 227 of 66,789 (absolute risk, 0.34%) in the standard-dose group (relative vaccine effectiveness, 23.7%; 95% confidence interval [CI], 6.6 to 37.7). Hospitalization for influenza occurred in 63 of 67,093 participants (absolute risk, 0.09%) in the high-dose group and in 92 of 66,789 (absolute risk, 0.14%) in the standard-dose group (relative vaccine effectiveness, 31.8%; 95% CI, 5.0 to 51.3). The incidence of serious adverse events appeared to be similar in the two trial groups. Among community-dwelling adults 65 to 79 years of age, there appeared to be fewer hospitalizations for influenza or pneumonia with high-dose inactivated influenza vaccine than with the standard dose. (Funded by Sanofi; GALFLU ClinicalTrials.gov number NCT06141655; EudraCT number, 2023-506977-36-00.).